Metastasis is the primary cause of mortality in patients with breast cancer and lacks effective therapeutic agents. Oridonin, an active diterpenoid compound isolated from Rabdosia rubescens, was identified to be the most potent anti-tumor ingredient. However, the molecular mechanisms responsible for its anti-metastatic effects remain unclear. In the present study, oridonin significantly suppressed the migration, invasion and adhesion of MDA-MB-231 and 4T1 breast cancer cells, and inhibited tube formation of human umbilical vein endothelial cells in a dose-dependent manner. The expression levels of epithelial-mesenchymal transition (EMT)-associated marker and the hypoxia inducible factor 1α (HIF-1α)/vascular endothelium growth factor (VEGF) signaling pathway mRNA and proteins were determined by reverse transcription-quantitative polymerase chain reaction and western blotting, respectively in vitro. The results demonstrated that oridonin effectively inhibited EMT as demonstrated by the significant increases in the expression levels of E-cadherin, and decreased expression of N-cadherin, Vimentin and Snail. In addition, oridonin exerted its anti-angiogenesis activity through significantly decreasing HIF-1α, VEGF-A and VEGF receptor-2 protein expression. Furthermore, oridonin was demonstrated to decrease the micro-vessel density as evidenced by the decreased expression of cluster of differentiation 31, a marker for neovasculature. In brief, oridonin inhibits tumor cell migration, invasion and adhesion, as well as tumor angiogenesis, which are mediated by suppressing EMT and the HIF-1α/VEGF signaling pathway.
Introduction
Breast cancer is the most fatal type of malignancy and the second leading cause of cancer-associated mortalities among women worldwide (1) . Approximately 90% of breast cancer-associated mortalities are due to metastasis to distant sites and not by the primary tumor itself. Therefore, screening for more effective compounds to control breast cancer metastasis has become the most important factor in improving breast cancer treatment.
During cancer progression, epithelial-mesenchymal transition (EMT) process is one of the primary mechanisms involved in breast cancer metastasis (2) . The process of EMT, during which cells lose epithelial characteristics and obtain mesenchymal properties, promotes cancer cell metastasis from primary tumors (3) . In addition to EMT, angiogenesis is another important factor that promotes tumor growth metastasis (4) . Accumulating evidence suggests that vascular endothelium growth factor (VEGF) is an essential factor in the development of tumor angiogenesis (5) . Hypoxia inducible factor 1α (HIF-1α), upstream of the VEGF, is associated with poor prognosis, and an increased risk of metastasis and mortality (6) . Hypoxia, a common characteristic of solid tumors, has been reported to reactivate EMT through HIF-1α in several tumor models (7) . HIF-1α directly or indirectly regulates EMT regulators, including Snail, Twist1 and Slug, and other transcription factors, and these transcription factors then trans activate EMT-associated genes, including E-cadherin, Vimentin and N-cadherin, to mediate EMT (8) . Accordingly, EMT and angiogenesis have become therapeutic targets for cancer metastasis treatment.
Oridonin, an active diterpenoid compound isolated from Rabdosia rubescens, is currently one of the most important active Chinese medicinal components. Notably, several studies reported that oridonin also demonstrates significant anti-metastasis effect in a variety of cancer types (9) . For instance, Dong et al (10) confirmed that oridonin inhibits tumor growth and metastasis through anti-angiogenesis by
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blocking the Notch signaling. Liu et al (11) indicated that the oridonin anti-tumor effect was primarily based on its anti-proliferation and anti-angiogenesis properties. Although accumulating evidence have indicated the anti-metastatic potential of oridonin, the effects and underlying mechanisms of oridonin on human breast cancer cells have not been fully elucidated. The present study investigated the effects of oridonin on EMT and angiogenesis in breast cancer, and its underlying mechanisms. Wound healing migration assay. Cell migration was detected using a wound-healing assay. MDA-MB-231 and 4T1 cells were cultured in 60-mm dishes at the density of 8x10 5 cells/dish to 100% confluence. Following wounding with a pipette tip, the cells were washed with PBS and serum-free medium with 4, 8 or 16 µM oridonin. Then, the cells were allowed to migrate for 24 h at 37˚C in 5% CO 2 . At predetermined time points (0, 3, 6, 9, 12 and 24 h), the widths of wound were measured using a ruler, and images of the cells were captured at 0 and 24 h under a light microscope with x100 magnification (IX71; Olympus Corporation, Tokyo, Japan).
Materials and methods

Animals
Transwell invasion assay. Cell invasion was detected using a Transwell assay. Following pre-treatment with 4, 8 or 16 µM oridonin for 24 h, MDA-MB-231 and 4T1 cells were harvested and seeded in the upper chamber of the Transwell chamber coated with Matrigel (BD Biosciences, San Jose, CA, USA) at a density of 4x10 4 cells/well in serum-free medium. The lower chambers were filled with standard medium. The cells were allowed to invade for 24 h incubated at 37˚C in 5% CO 2 . The invading cells were fixed with 4% methanol for 20 min at room temperature. Cell numbers were counted in five separate fields using a computer-based microcopy imaging DP2-BSW system (version 1.3; Olympus Corporation).
Cell adhesion assay. Following pre-treatment with 4, 8 or 16 µM oridonin for 24 h, MDA-MB-231 and 4T1 cells were harvested, re-suspended in serum free medium at the density of 2x10 5 cells/well and seeded to the 24-well plates coated with fibronectin (10 ng/ml). Following further incubations for 5, 15 and 30 min, non-adherent cells were removed by three PBS washes. The adherent cells were fixed with 4% methanol for 20 min at room temperature and counted in five separate fields under a light microscope with x200 magnification (Olympus Corporation).
Tube formation assay. AHUVEC capillary-like formation assay was performed on Matrigel (BD Biosciences) (13) . Matrigel was added into 96-well plate and cultured in 37˚C for 2 h to solidify the Matrigel. Following pre-treatment with 4, 8 or 16 µM oridonin for 24 h, HUVECs were seeded in plates at the density of 8x10 3 cells/well. According to previous methods (14, 15) , morphological changes (formation of capillary-like structures) of the cells and tube formation were observed under a phase-contrast microscope and imaged at x200 magnification after a 6 h incubation.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Following pre-treatment with 4, 8 or 16 µM oridonin for 24 h, the total RNA of MDA-MB-231 or 4T1 cells was extracted using TRIzol reagent (Life Technologies; Thermo Fisher Scientific, Inc.). Reverse transcription was performed with the fast quant RT kit (Tiangen Biotech Co., Ltd., Beijing, China) according to the manufacturer's protocol. The PCR mixture volume was 25 µl, including 12.5 µl SYBR green mix (Tiangen Biotech Co., Ltd.), 0.2 µl cDNA, 1.5 µl primer/mix (10 µM of each primer) and 10.8 µl RNAse-free H 2 O. The experiment was then set up using the following PCR program on a ABI 7500 system (Applied Biosystems; Thermo Fisher Scientific, Inc.): 95˚C for 15 min, 1 cycle; followed by 40 cycles of 95˚C for 10 sec, 60˚C for 20 sec and 72˚C for 30 sec. Specific primers were designed using Gene Runner software (version 6.5.48) produced by Dr. Spruyt Michael (Mahwah, NJ, USA) and Dr. Buquicchio Frank (Old Tappan, NJ, USA). Specific primers were synthesized by Beijing Century Aoke Biotechnology Co., Ltd. (Beijing, China). The specific primers are presented in Table I . The Cq value was automatically calculated by 7500 software (version 2.0.5, Applied Biosystems; Thermo Fisher Scientific, Inc.), the Ct values were all normalized against the quantity of the β-actin control RNA, and the relative quantification of gene expression was calculated by the 2 -∆∆Cq method according to the formula: ∆Cq (target gene)=Cq (target gene)-Cq (control gene) (16) . All assays were performed in triplicate and independently repeated three times.
Western blotting assay. Western blotting assay was used for the detection of E-cadherin, N-cadherin, Vimentin, Snail, HIF-1α, VEGF-A and VEGFR-2 expression levels in MDA-MB-231 and 4T1 cells. Following pre-treatment with 4, 8 or 16 µM oridonin for 24 h, the 10 µg protein lysates from cultured cells were separated by 10% SDS-PAGE systems and transferred to polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). Following blocking with 5% skim milk in TBS containing 0.1% Tween 20 (TBST) for 2 h at room temperature, the membranes were incubated with the aforementioned primary antibodies at 1:500 to 1:1,000 dilutions with 5% BSA in TBST overnight at 4˚C. The antibodies and dilution factors were as follows: E-cadherin (1:1,000); N-cadherin (1:1,000); Vimentin (1:1,000); Snail (1:1,000); HIF-1α (1:500); VEGF-A (1:800); and VEGFR-2 (1:800). The blots were washed with PBS and incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. Membranes were visualized using enhanced chemiluminescencekit (EMD Millipore) and were imaged using G-BOX (Gene Company, Ltd., Hong Kong, China). The bands analyzed using Image Pro Plus 6.0 software (Media Cybernetics Inc., Rockville, MD, USA).
Animal experiments. The 4T1 (3x10 6 ) cells were subcutaneously inoculated into the mammary fat pad of mice. Once each animal developed distinct tumors, animals were randomly segregated into 1 vehicle group and 3 oridonin group (n=6/group) and respectively treated with 0.5% DMSO (the vehicle) or oridonin at doses of 2.5, 5 or 10 mg/kg. All administrations were carried out via intratumoral injections every 3 days four times. Bodyweight and tumor volumes were measured twice a week. The tumor volume was estimated using the following formula: (ab) 2 /2, where a and b are tumor length and width, respectively (17) . The animals were sacrificed on day 10, and the tumors of the oridonin-treated and vehicle-treated groups were excised.
Immunohistochemical analysis. Immunohistochemical analysis was performed to evaluate the tumor vessels density. Tumor tissues were fixed in 8% neutral formaldehyde at room temperature, embedded in paraffin and cut into sections of 5-mm thickness. Following antigen retrieval, tissue sections were blocked with PBS containing blocking serum (Gibco; Thermo Fisher Scientific, Inc.) for 2 h at room temperature and were incubated overnight at 4˚C with primary antibodies against CD31 at 1:500 dilutions with 5% BSA in TBST (cat. no. AR0195; Boster, Wuhan, China). Subsequently, sections were incubated with universal HRP-conjugated secondary antibodies (OriGene Technologies, Inc., Beijing, China) for 30 min. The chromogenic reaction was performed using DAB peroxidase substrate (OriGene Technologies, Inc.) by incubating sections for 2 min at room temperature. Images were captured with an upright fluorescent microscope (BX51; Olympus Corporation). The number of CD31-positive vessels (brown staining) in five randomly selected fields (magnification, x200) was counted and vessels were calculated as the sum of CD31-positive vessels in the five fields (18) .
Statistical analysis. Statistical analysis was performed using SPSS 19.0 (IBM Corp., Armonk, NY, USA). All data are presented as the mean ± standard deviation. One-way analysis of variance was used to analyze the difference between the groups. The least significant difference method was used to analyze post-hoc multiple comparisons. P-values were two-tailed; P<0.05 was considered to indicate a statistically significant difference.
Results
Effects of oridonin on the viability of MDA-MB-231, 4T1
and MCF-10A cells. Oridonin has a molecular weight of 364.44 g/mol and its molecular structure is presented in Fig. 1A . Firstly, the inhibitory effects of oridonin on the proliferation of MDA-MB-231 and 4T1 cells were investigated using an MTT assay. The results demonstrated that oridonin treatment caused significant cell proliferation inhibition in a dose-dependent manner in MDA-MB-231 and 4T1 cells (Fig. 1B and C (Fig. 1D) .
Thus, in the subsequent experiments, the concentrations 4, 8 and 16 µM oridonin were chosen for further investigation. For all in vitro experiments, an untreated group was used as the control.
Oridonin inhibits the migration and invasion of MDA-MB-231 and 4T1 cells.
In the absence of oridonin (control group), MDA-MB-231 and 4T1 cells exhibited high migratory and invasive capabilities as indicated through the complete healing of the wound scratch and penetration of cells through the Matrigel-coated filters. The migration (Fig. 1E-H) and invasion ( Fig. 2A-C ) of cancer cells was significantly suppressed by oridonin in a concentration-dependent manner. 
Oridonin inhibits the adhesion of MDA-MB-231 and 4T1 cells. Fibronectin was used as the basement membrane to mimic the adhesion of MDA-MB-231 and 4T1 cells (19).
Following pre-treatment with 4, 8 and 16 µM oridonin, the number of cells adhering to the fibronectin significantly decreased compared with the control group ( Fig. 2D and E) .
The results demonstrated that oridonin inhibited the adhesion of MDA-MB-231 and 4T1 cells to fibronectin.
Oridonin inhibits tube formation of HUVECs cells in vitro.
To investigate the effect of oridonin on angiogenesis in vitro, a capillary tube formation assayusing HUVECs on Matrigel was performed. As presented in Fig. 2F and G, the capillary tube formation of HUVECs was significantly inhibited after 24 h exposure to oridonin when compared with the control group.
Oridonin regulates the expression of EMT markers in MDA-MB-231 and 4T1 cells.
The results demonstrated that the effects of oridonin were dose-dependent, with significantly increasing expression levels of E-cadherin, and significantly decreasing expression levels of N-cadherin, Vimentin and Snail in MDA-MB-231 and 4T1 cells compared with the control group (Fig. 3) .
Oridonin suppresses the HIF-1α/VEGF signaling pathway in MDA-MB-231 and 4T1 cells.
The expression levels of angiogenic molecules, including HIF-1α, VEGF-A and VEGFR-2 were measured in MDA-MB-231 and 4T1 cells using western blotting. The data revealed that the levels of HIF-1α, VEGF-A and VEGFR-2 were significantly reduced following oridonin treatment (Fig. 4A-C) .
Oridonin inhibits the tumor growth and angiogenesis in vivo.
To assess the effect of oridonin on tumor growth and angiogenesis in vivo, BALB/c mice were implanted with 4T1 cells. Following the injection of 4T1 cells, the tumors were allowed to grow, subsequently mice were treated with different concentrations of oridonin. During the experiment, no mice presented multiple tumors. The longest diameter exhibited by a single subcutaneous tumor was ~6 mm. No significant changes in the body weight of mice were noted followed oridonin treatment (Fig. 5A) . The mean tumor volume after 9 days of treatment was significantly decreased in the group treated with indicated concentrations (2.5, 5 and 10 mg/kg) of oridonin (Fig. 5B) . After 9 days of treatment, the mice were sacrificed; and the tumors were excised and weighted. The mean tumor weight after 9 days treatment was significantly decreased in all three oridonin treatment groups compared with the vehicle control (Fig. 5C) . Additionally, the data demonstrated that oridonin significantly downregulated CD31 expression when compared with the control group ( Fig. 5D and E) . However, a limitation of the present study was absence of the determination of CD31 expression in the tissues by western blotting.
Discussion
Recently, oridonin has attracted increasing attention due to its excellent antitumor activity against various cancer types, including breast cancer (20) . The present study was designed to investigate the anti-metastatic effect of oridonin on breast cancer. The results of the present study demonstrated that oridonin significantly suppressed the migratory and invasive potential of MDA-MB-231 and 4T1 cells in vitro possibly by inhibition of EMT and angiogenesis via downregulation of the HIF-1α/VEGF signaling pathway. As numerous literatures have reported, oridonin effectively inhibited the proliferation of a variety of cancer cells, including those from prostate (LNCaP, DU145, PC3), breast (MCF-7, MDA-MB231) and non-small cell lung (NCI-H520, NCI-H460, NCI-H1299) cancer, and acute promyelocytic leukemia (NB4) and glioblastoma multiforme (U118, U138) with the ED 50 range between 1.8 and 7.5 mg/ml (21) . The majority of reported researches have investigated the cytotoxicity of oridonin. However, in the current study, the anti-metastatic ability of breast cancer cells below the cytotoxicity dosage was focused upon. Firstly, an MTT assay was performed to evaluate the inhibitory effects of oridonin on the proliferation of MDA-MB-231 and 4T1 cells. Oridonin significantly inhibited the proliferation of MDA-MB-231 and 4T1 cells in a dose-dependent manner. In order to eliminate the influence of cytotoxic effects of oridonin on the migratory and invasive capacities of cells, non-cytotoxic concentrations of 4, 8 and 16 µM oridonin were chosen for further investigation. Cell invasion, migration and adhesion assays were performed to evaluate the anti-migratory ability of oridonin. Based on our previous study (22) , the time of cell exposure to oridonin in the aforementioned experiments were as follows: Transwell invasion assay 24 h; wound healing migration assay To the best of our knowledge, the results of the present study are the first to investigate the anti-migratory and invasive ability of oridonin on breast cancer cells below the cytotoxicity dosage. The metastasis potential of cancer cells is primarily determined by the migratory, invasive and adhesive capacities, which is commonly determined with wounding healing, Transwell chamber with Matrigel-coated filter and adhesion assays, all three of which were used in the present study (23) . The data demonstrated that oridonin effectively attenuated the migratory, invasive and adhesive abilities of MDA-MB-231 and 4T1 cells. In addition, to investigate the effect of oridonin on angiogenesis in vitro, a capillary tube formation assay was performed on HUVECs using Matrigel. It was observed that oridonin significantly inhibited capillary tube formation of HUVECs.
EMT is an essential step that occurs during cancer development. The initiation of EMT arises from a loss of cell polarity and cell-cell adhesion, which enhances the cancer cells migratory and invasive abilities. In breast cancer, EMT may be induced by multiple extracellular signaling factors, including tumor growth factor-β, Notch, phosphatidylinositol 3-kinase/protein kinase B, Wnt and receptor tyrosine kinases (24, 25) . The snail transcriptional repressor complex promotes EMT by repressing the junction component E-cadherin (26) . Decreased E-cadherin has been associated with cancer cell migration, invasion and the advanced cancer stages, as well as metastasis, leading to poor prognosis in breast cancer (27) . The results of the present study demonstrated that the expression of E-cadherin was significantly increased, and the expression of Snail, N-cadherin and Vimentin was significantly decreased following exposure to oridonin, indicating that the inhibition of EMT is involved in the anti-migratory and anti-invasive effects of oridonin.
Breast cancer shares the characteristics of tissue hypoxia, particularly when the tumor grows too quickly and angiogenesis fails to catch up with the speed of tumor growth. HIF-1α is a key regulatory molecule that responds to hypoxia in cell migration, invasion, adhesion and angiogenesis (28) . In addition, VEGF is associated with the induction of neovascularization in human breast cancer, which is mediated by multiple interacting genetic and environmental signals (29) . A hypoxic microenvironment maybe a leading cause of angiogenesis, which is an important determinant of malignant tumor development, by activation of the expression of VEGF via HIF-1α (30) . In the in vitro study, it was revealed that oridonin exhibited an anti-angiogenesis effect. It is well known that angiogenesis is important for tumor metastasis. Thus, we hypothesized that the mechanism underlying the anti-migratory and anti-invasive effects of oridonin is associated with its anti-angiogenesis effect. Thus, an in vivo study was performed to confirm this hypothesis. As previously reported (31) , the subcutaneously xenograft model is a better model to evaluate the effect of adrug or compound on angiogenesis using CD31 staining. Thus, this model was chosen in the present study. A metastatic mouse model will be established to evaluate the anti-metastatic effect of oridonin in future studies. The current study demonstrated that oridonin effectively inhibited tumor growth and angiogenesis in vivo. Further investigations revealed that the expression of HIF-1α, VEGF-A and VEGFR-2 was significantly decreased, indicating that the inhibition of angiogenesis was involved in the antitumor effect of oridonin. Loss-of-function and gain-of-function experiments will be performed to confirm the mechanism underlying the antitumor effects of oridonin in further studies.
In conclusion, the findings of the present study suggest that oridonin significantly inhibited the migration, invasion, adhesion and angiogenesis through inhibition of EMT and downregulation of the HIF-1α/VEGF signal pathway in vitro and in vivo. Thus, oridonin may be a potentially useful anti-metastatic agent in breast cancer treatment.
